For patients with N2-N3 disease who have a clinical PR or SD with platinum-based chemotherapy, switch maintenance avelumab would be quite reasonable since such patients were eligible for the JAVELIN Bladder-100 phase III trial (and benefit was seen regardless of PD-L1 status, although benefit appear...